Evaluation of Outcomes From Treatment of Benign or Malignant Gastrointestinal Diseases

This study will be a retrospective, registry study collecting data of patients who were diagnosed with benign or malignant gastrointestinal diseases. Data will be collected from patient's chart retrospectively once the patients have completed proper treatment follow up with physicians' practice.

Study Overview

• Status: Enrolling by invitation
• Conditions: Gastrointestinal Disease

Detailed Description

It is reported in the literature that the treatment of any gastrointestinal disease process, whether benign or malignant, continues to be a huge challenge. For example, patients with gastrointestinal cancer continue to be diagnosed at an advanced stage with medical and surgical options that are improving in terms of outcome measurements but with much more room for improvement. The goal is to continue to review our treatment outcomes to further improve overall survival, overall symptom control, mortality and morbidity.

The main aim of this study is to evaluate and compare the outcomes from our treatment of benign or malignant gastrointestinal diseases through medical chart review.

There is a need to understand and improve the current diagnosis and treatment algorithm for gastrointestinal pathologies. Continued evaluation and study is imperative to ensure that national guidelines are improving to enhance patient cure and/or recovery.

• Study Type: Observational
• Enrollment (Estimated): 1000

Contacts and Locations

Study Locations

• United States
  • Texas
    • Richardson, Texas, United States, 75082
      • Methodist Richardson Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients who were diagnosed with benign or malignant gastrointestinal diseases.

Description

Inclusion Criteria:

• All patients diagnosed and treated for gastrointestinal diseases, benign or malignant from 2005 to 2030.
• Age ≥18 years

Exclusion Criteria:

• Patients that are not diagnosed with or treated for gastrointestinal diseases
• Age <18 years

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall survival	from day of diagnosis or procedure to death date	Jan 2005 - Jan 2030
Overall symptom	Difficulty swallowing, Heartburn, Regurgitation, Chest pain, Weight Loss, Quality of life	Jan 2005 - Jan 2030
Mortality	death or life	Jan 2005 - Jan 2030
Morbidity	yes or no to individual disease	Jan 2005 - Jan 2030

Collaborators and Investigators

• Sponsor: Methodist Health System
• Investigators: Principal Investigator: Dhiresh R Jeyarajah, Methodist Health System

Study record dates

Study Major Dates

• Study Start (Actual): January 7, 2021
• Primary Completion (Estimated): May 17, 2030
• Study Completion (Estimated): May 17, 2030

Study Registration Dates

• First Submitted: November 18, 2020
• First Submitted That Met QC Criteria: November 9, 2021
• First Posted (Actual): November 10, 2021

Study Record Updates

• Last Update Posted (Actual): April 22, 2026
• Last Update Submitted That Met QC Criteria: April 17, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Gastrointestinal Diseases
• Other Study ID Numbers: 031.HPB.2020.R

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No